Literature DB >> 3725640

Vancomycin pharmacokinetics in infants: relationships to indices of maturation.

D H Schaible, M L Rocci, G A Alpert, J M Campos, M H Paul, R A Polin, S A Plotkin.   

Abstract

The relationships between steady state pharmacokinetics of vancomycin and various indices of maturation were examined in 11 infants (gestational ages, 27 to 40 weeks; postconceptional ages (PCA), 29 to 48 weeks). Vancomycin was administered as a 10-mg/kg iv infusion over 30 minutes. Serial blood samples were obtained over a dosage interval and vancomycin serum concentrations were determined by fluorescence polarization immunoassay. Model-independent pharmacokinetic data analysis yielded values for vancomycin systemic clearance (CL), volume of distribution (Vdss) and half-life ranging from 0.032 to 0.484 liter/hour, 0.44 to 2.5 liters and 3.5 to 9.6 hours respectively. Stepwise multiple regression analysis indicated that PCA was the best single variable model to predict vancomycin clearance as described, namely: CL (liters/hour) = 0.0224 PCA (weeks) - 0.639 (r = 0.91; P less than 0.0001). Other more complex models using a combination of patient variables only modestly improved the ability to explain the variability in vancomycin clearance. Vdss was strongly related to body weight (r = 0.93; P less than 0.0001) Vdss = 0.563 weight (kg) + 0.052). Our results suggest that postnatal alterations in vancomycin disposition are related to maturational changes in body composition and renal function. These data also suggest that vancomycin doses smaller than those previously recommended may be used to achieve therapeutic steady state vancomycin serum concentrations during the first 2 months of life.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3725640     DOI: 10.1097/00006454-198605000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  15 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

Review 2.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.

Authors:  F Pawlotsky; A Thomas; M F Kergueris; T Debillon; J C Roze
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

4.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

Review 5.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 6.  An updated comparison of drug dosing methods. Part IV: Vancomycin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

7.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 8.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants.

Authors:  S M Lisby-Sutch; M C Nahata
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Antimicrobial therapy in neonates, infants and children.

Authors:  R D Brown; D M Campoli-Richards
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.